TRIBEKA is an initiative of Barcelonaβeta Brain Research Center (BBRC) and the University of Edinburgh, driven to identify the cerebral alterations prior to the onset of the symptoms of Alzheimer's disease and other neurodegenerative diseases.
The mission of the consortium is to generate an open access neuroimaging platform that allows to offer widely characterized information to advance the design of new treatments. All the information collected in the project will be offered to the global scientific community, through the Alzheimer's Association Interactive Network.
The project will have the data of more than 1,000 healthy participants between 40 and 65 years of age, from the cohorts of prevention of the different centers: the Alfa Study in Spain and Prevent in the United Kingdom. In this sense, the platform will make available to the scientific and pharmaceutical community the results of the different tests that are carried out periodically by the participants of these studies.
TRIBEKA participants will be subjected to magnetic resonance imaging tests, positron emission tomography (PET) and cognitive tests. They will also provide their clinical history and family history, information about their habits of life, and blood, saliva, urine and cerebrospinal fluid samples for the analysis and discovery of biomarkers.
The consortium is financed by the Alzheimer's Association and an international anonymous charity foundation. The project was presented by Dr. José Luis Molinuevo, in the framework of the international congress of the Alzheimer's Association, held in July 2017 in London.
For more information about the project or requests for collaboration, you can contact firstname.lastname@example.org.
Principal Investigator of TRIBEKA
José Luis Molinuevo, scientific director of the Alzheimer's Prevention Program.
Molinuevo is co-author of more than 280 scientific articles with more than 10,000 citations in prestigious journals, and a 53 h index. In addition, he participates in networks related to the standardization of procedures and clinical criteria of Alzheimer’s disease, such as the Alzheimer Biomarker Standarization Initiative, the International Working Group, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research framework, the CSF Appropriate Use Criteria Workgroup, the Standardization of CSF Preanalytics Working Group and the Subjective Cognitive Decline Initiative (SCD-I) Working Group.